What Is the First-Line Treatment for Mycosis Fungoides at Clinical Stage IIIA or IIIB (Erythroderma, T4)?

Clinical Scenario

This protocol addresses patients with mycosis fungoides at clinical stage IIIA or IIIB, defined by erythroderma (T4 skin involvement). Erythrodermic MF represents advanced skin-predominant disease and is the defining feature driving first-line treatment selection at this stage.

First-Line Treatment Approach

Evidence-based guidance for this stage recognises several therapeutic approaches as equivalent first-line options. These span systemic modalities as well as skin-directed interventions, and certain options have specific eligibility requirements that determine their applicability to individual patients.

The complete regimen — including which options apply, eligibility criteria, and sequencing — is available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ejca.2023.113343

Recommendations for first-line treatment of MF stage IIIA and B.
It thus still applies that ECP can be safely applied alone or in combination with other systemic and skin directed therapies and its use is recommended mainly in erythrodermic MF and SS without high level evidence on superiority of one combination over the other or over ECP alone.

View source ↗